These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 20368395

  • 1. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
    Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R, Drusano GL.
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2646-54. PubMed ID: 20368395
    [Abstract] [Full Text] [Related]

  • 2. Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.
    Louie A, Liu W, VanGuilder M, Neely MN, Schumitzky A, Jelliffe R, Fikes S, Kurhanewicz S, Robbins N, Brown D, Baluya D, Drusano GL.
    J Infect Dis; 2015 Apr 15; 211(8):1326-33. PubMed ID: 25362196
    [Abstract] [Full Text] [Related]

  • 3. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant.
    Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A.
    Antimicrob Agents Chemother; 2009 Jun 15; 53(6):2266-73. PubMed ID: 19289521
    [Abstract] [Full Text] [Related]

  • 4. Transcriptional Analysis of MexAB-OprM Efflux Pumps System of Pseudomonas aeruginosa and Its Role in Carbapenem Resistance in a Tertiary Referral Hospital in India.
    Choudhury D, Das Talukdar A, Dutta Choudhury M, Maurya AP, Paul D, Dhar Chanda D, Chakravorty A, Bhattacharjee A.
    PLoS One; 2015 Jun 15; 10(7):e0133842. PubMed ID: 26221722
    [Abstract] [Full Text] [Related]

  • 5. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I, Kaynar-Tascioglu J, Kaya B, Goktas P.
    Int J Antimicrob Agents; 2002 Nov 15; 20(5):384-6. PubMed ID: 12431875
    [Abstract] [Full Text] [Related]

  • 6. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
    Visalli MA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1998 Apr 15; 42(4):953-5. PubMed ID: 9559819
    [Abstract] [Full Text] [Related]

  • 7. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B.
    Lim TP, Lee W, Tan TY, Sasikala S, Teo J, Hsu LY, Tan TT, Syahidah N, Kwa AL.
    PLoS One; 2011 Apr 15; 6(12):e28177. PubMed ID: 22162759
    [Abstract] [Full Text] [Related]

  • 8. The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
    Drusano GL, Neely MN, Yamada WM, Duncanson B, Brown D, Maynard M, Vicchiarelli M, Louie A.
    Antimicrob Agents Chemother; 2018 Dec 15; 62(12):. PubMed ID: 30249700
    [Abstract] [Full Text] [Related]

  • 9. Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients.
    Zhao L, Li X, He X, Jian L.
    BMC Pharmacol Toxicol; 2020 Mar 04; 21(1):20. PubMed ID: 32131897
    [Abstract] [Full Text] [Related]

  • 10. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP.
    Diagn Microbiol Infect Dis; 2007 Feb 04; 57(2):153-61. PubMed ID: 16930925
    [Abstract] [Full Text] [Related]

  • 11. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
    Zhanel GG, Mayer M, Laing N, Adam HJ.
    Antimicrob Agents Chemother; 2006 Jun 04; 50(6):2228-30. PubMed ID: 16723591
    [Abstract] [Full Text] [Related]

  • 12. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
    Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL.
    Antimicrob Agents Chemother; 2010 Jun 04; 54(6):2638-45. PubMed ID: 20308371
    [Abstract] [Full Text] [Related]

  • 13. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
    Montero MM, Domene Ochoa S, López-Causapé C, VanScoy B, Luque S, Sorlí L, Campillo N, Padilla E, Prim N, Segura C, Pomar V, Rivera A, Grau S, Ambrose PG, Oliver A, Horcajada JP.
    J Glob Antimicrob Resist; 2019 Sep 04; 18():37-44. PubMed ID: 31154007
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J, Mazucheli J, Barros JPDR, Szczerepa MMDA, Nishiyama SAB, Carrara-Marroni FE, Sy S, Fidler M, Sy SKB, Tognim MCB.
    Antimicrob Agents Chemother; 2019 Jun 04; 63(6):. PubMed ID: 30910903
    [Abstract] [Full Text] [Related]

  • 15. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.
    Lister PD, Wolter DJ, Wickman PA, Reisbig MD.
    J Antimicrob Chemother; 2006 May 04; 57(5):999-1003. PubMed ID: 16513915
    [Abstract] [Full Text] [Related]

  • 16. Structural changes and differentially expressed genes in Pseudomonas aeruginosa exposed to meropenem-ciprofloxacin combination.
    Siqueira VL, Cardoso RF, Caleffi-Ferracioli KR, Scodro RB, Fernandez MA, Fiorini A, Ueda-Nakamura T, Dias-Filho BP, Nakamura CV.
    Antimicrob Agents Chemother; 2014 Jul 04; 58(7):3957-67. PubMed ID: 24798291
    [Abstract] [Full Text] [Related]

  • 17. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
    Lister PD, Wolter DJ.
    Clin Infect Dis; 2005 Feb 15; 40 Suppl 2():S105-14. PubMed ID: 15712098
    [Abstract] [Full Text] [Related]

  • 18. Contribution of mexAB-oprM and mexXY (-oprA) efflux operons in antibiotic resistance of clinical Pseudomonas aeruginosa isolates in Tabriz, Iran.
    Goli HR, Nahaei MR, Rezaee MA, Hasani A, Samadi Kafil H, Aghazadeh M, Sheikhalizadeh V.
    Infect Genet Evol; 2016 Nov 15; 45():75-82. PubMed ID: 27562333
    [Abstract] [Full Text] [Related]

  • 19. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y, Kobayashi Y.
    Jpn J Antibiot; 2007 Dec 15; 60(6):394-403. PubMed ID: 18447209
    [Abstract] [Full Text] [Related]

  • 20. [Bactericidal effect of levofloxacin injection in combination with meropenem against Pseudomonas aeruginosa using an in vitro simulation model with a hollow fiber system].
    Uoyama S, Kanda H, Yoshida K, Hoshino K.
    Jpn J Antibiot; 2012 Dec 15; 65(6):355-63. PubMed ID: 23593732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.